KABRADGPharmaceuticals
Kabra Drugs Ltd — Profit & Loss Statement
₹24.58
-3.19%
Kabra Drugs Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Tax Rate For Calcs | 0.30 | 0.00 | 0.00 | 0.00 | — |
| Normalized EBITDA | -1.08 Cr | -0.74 Cr | -0.34 Cr | -0.18 Cr | — |
| Total Unusual Items | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Total Unusual Items Excluding Goodwill | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income From Continuing Operation Net Minority Interest | -1.09 Cr | -0.74 Cr | -0.34 Cr | -0.19 Cr | — |
| Reconciled Depreciation | 73000.00 | 0.00 | 0.00 | 99791.00 | — |
| Reconciled Cost Of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | — |
| EBITDA | -1.08 Cr | -0.74 Cr | -0.34 Cr | -0.18 Cr | — |
| EBIT | -1.09 Cr | -0.74 Cr | -0.34 Cr | -0.19 Cr | — |
| Net Interest Income | 0.00 | 0.00 | 60663.00 | -1091.00 | — |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Normalized Income | -1.09 Cr | -0.74 Cr | -0.34 Cr | -0.19 Cr | — |
| Net Income From Continuing And Discontinued Operation | -1.09 Cr | -0.74 Cr | -0.34 Cr | -0.19 Cr | — |
| Total Expenses | 1.73 Cr | 0.74 Cr | 0.34 Cr | 0.19 Cr | — |
| Diluted NI Availto Com Stockholders | -1.09 Cr | -0.74 Cr | -0.34 Cr | -0.19 Cr | — |
| Net Income Common Stockholders | -1.09 Cr | -0.74 Cr | -0.34 Cr | -0.19 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | -1.09 Cr | -0.74 Cr | -0.34 Cr | -0.19 Cr | — |
| Net Income Including Noncontrolling Interests | -1.09 Cr | -0.74 Cr | -0.34 Cr | -0.19 Cr | — |
| Net Income Continuous Operations | -1.09 Cr | -0.74 Cr | -0.34 Cr | -0.19 Cr | — |
| Tax Provision | 5000.00 | 0.00 | 0.00 | 0.00 | — |
| Pretax Income | -1.09 Cr | -0.74 Cr | -0.34 Cr | -0.19 Cr | — |
| Other Non Operating Income Expenses | 0.64 Cr | — | 64000.00 | — | — |
| Special Income Charges | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Non Operating Interest Income Expense | 0.00 | 0.00 | 60663.00 | -1091.00 | — |
| Interest Expense Non Operating | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Operating Income | -1.73 Cr | -0.74 Cr | -0.34 Cr | -0.19 Cr | — |
| Operating Expense | 1.73 Cr | 0.74 Cr | 0.34 Cr | 0.19 Cr | — |
| Other Operating Expenses | 1.03 Cr | 0.34 Cr | 0.03 Cr | 0.05 Cr | — |
| Depreciation And Amortization In Income Statement | 73000.00 | 0.00 | 0.00 | 99791.00 | — |
| Depreciation Income Statement | 73000.00 | 0.00 | 0.00 | 99791.00 | — |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Cost Of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Operating Revenue | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Interest Income | — | 0.00 | 63764.00 | 0.00 | 0.00 |
| Rent Expense Supplemental | — | 0.04 Cr | 0.02 Cr | 0.02 Cr | 0.02 Cr |
| Diluted Average Shares | — | 0.44 Cr | 0.44 Cr | 0.44 Cr | 0.44 Cr |
| Basic Average Shares | — | 0.44 Cr | 0.44 Cr | 0.44 Cr | 0.44 Cr |
| Diluted EPS | — | -1.68 | -0.77 | -0.42 | -0.41 |
| Basic EPS | — | -1.68 | -0.77 | -0.42 | -0.41 |
| Total Other Finance Cost | — | 5468.00 | 3101.00 | 1091.00 | — |
| Interest Income Non Operating | — | 0.00 | 63764.00 | 0.00 | 0.00 |
| Selling General And Administration | — | 0.04 Cr | 0.06 Cr | 0.01 Cr | 0.01 Cr |
| Selling And Marketing Expense | — | 0.02 Cr | 87110.00 | 69026.00 | 0.00 |
| General And Administrative Expense | — | 0.02 Cr | 0.05 Cr | 80000.00 | 0.01 Cr |
| Rent And Landing Fees | — | 0.04 Cr | 0.02 Cr | 0.02 Cr | 0.02 Cr |
| Net Income Extraordinary | — | — | — | — | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Kabra Drugs Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.